Moderna received FDA approval for its new mRNA-based flu shot for older adults after months of regulatory questioning.

The Food and Drug Administration on Wednesday approved the U.S.’s first flu shot that uses mRNA technology: mFlusiva, from ...

The vaccine could give Moderna a foothold in seasonal flu and strengthen the case for mRNA shots against fast-changing ...

Previously, the COVID-19 immunizations made by Pfizer and Moderna were the only mRNA vaccines on the market.

This flu shot, mFlusiva, was shown in a clinical trial to be up to 27 percent more effective than a standard flu jab ...

The Food and Drug Administration just approved the new type of flu vaccine for adults ages 50 and older. It relies on the ...

The decision caps a seven-month review that included a rare refusal to consider the shot at all.

In a first, the U.S. has approved an influenza vaccine that relies on mRNA technology—the same technology that underpinned ...

The FDA has approved Moderna's flu vaccine for people aged 50 and older, marking the first approval of a messenger RNA-based ...

The FDA has approved Moderna's mRNA-based seasonal flu vaccine for adults 50 and older, marking the first such approval in the U.S.

Moderna’s mRNA-based flu vaccine, mFlusiva, is approved by the Food and Drug Administration for adults aged 50 and over.

The U.S. Food and Drug Administration has approved a new seasonal flu vaccine from Moderna that uses mRNA technology, the ...